Skip to main content
Fig. 4 | Biomarker Research

Fig. 4

From: Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients

Fig. 4

Adjusted TMI for screening responders in the combined POPLAR and OAK cohorts. A TMI-based stratification of docetaxel-treated or atezolizumab-treated NSCLC patients from the POPLAR cohort plus the OAK cohort. B Mutation patterns and clinical characteristics of NSCLC patients who received docetaxel and atezolizumab. C Kaplan-Meier curves of the adjusted TMI-based stratification of NSCLC patients who received monotherapy with docetaxel or atezolizumab

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us